BRPI0511448A - anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências - Google Patents

anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências

Info

Publication number
BRPI0511448A
BRPI0511448A BRPI0511448-9A BRPI0511448A BRPI0511448A BR PI0511448 A BRPI0511448 A BR PI0511448A BR PI0511448 A BRPI0511448 A BR PI0511448A BR PI0511448 A BRPI0511448 A BR PI0511448A
Authority
BR
Brazil
Prior art keywords
tnf
high affinity
alpha antibodies
antibody
generation method
Prior art date
Application number
BRPI0511448-9A
Other languages
English (en)
Inventor
Roberto Crea
Arvind Rajpal
Toshi Takeuchi
Guido Cappuccilli
Jennifer Jones
Original Assignee
Bioren Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioren Inc filed Critical Bioren Inc
Publication of BRPI0511448A publication Critical patent/BRPI0511448A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTICORPOS ANTI-TNF-ALFA DE ALTA AFINIDADE, MéTODO PARA A GERAçãO DOS MESMOS E BIBLIOTECA DE SEQüêNCIAS. A presente invenção refere-se a um anticorpo anti-TNF-<244> humano isolado, ou parte de ligação a antígeno do mesmo, contendo pelo menos uma cadeia de anticorpo V~ L~ ou V~ H~ de alta afinidade que é eficaz, quando substituída pela cadeia V~ L~ ou V~ H~ correspondente do anticorpo anti-TNF-<244> scFv que apresenta a seqüência SEQ ID NO: 1, para ligar-se a TNF-<244> humano com uma taxa constante K~ off~ que é pelo menos 1,5 vez menor que aquela do anticorpo que apresenta SEQ ID NO: 1, quando determinada sob condições idênticas.
BRPI0511448-9A 2004-07-06 2005-07-06 anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências BRPI0511448A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58648704P 2004-07-06 2004-07-06
PCT/US2005/023957 WO2006014477A1 (en) 2004-07-06 2005-07-06 HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD

Publications (1)

Publication Number Publication Date
BRPI0511448A true BRPI0511448A (pt) 2007-12-26

Family

ID=34975191

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511448-9A BRPI0511448A (pt) 2004-07-06 2005-07-06 anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências

Country Status (6)

Country Link
US (1) US20060024308A1 (pt)
EP (1) EP1769003A1 (pt)
BR (1) BRPI0511448A (pt)
CA (1) CA2573259A1 (pt)
MX (1) MX2007000104A (pt)
WO (1) WO2006014477A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
CA2634080A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
CN101400703B (zh) 2006-02-01 2013-05-08 赛法隆澳大利亚控股有限公司 结构域抗体构建体
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
EP2225276B1 (en) 2007-12-31 2014-04-23 Bayer Intellectual Property GmbH Antibodies to tnf alpha
US9102711B2 (en) * 2007-12-31 2015-08-11 Xoma Technology Ltd. Methods and materials for targeted mutagenesis
IT1394281B1 (it) * 2009-01-19 2012-06-06 Zardi Processo per la produzione di proteine di fusione polivalenti e polispecifiche utilizzando come struttura portante l'uteroglobina e prodotti cosi' ottenuti.
EP2409992B1 (en) * 2009-03-20 2017-10-25 Danyang Zhengyuan Biotech Co. Ltd. A human anti-tumor necrosis factor alpha monoclonal antibody and use thereof
US8722860B2 (en) * 2009-04-16 2014-05-13 Abbvie Biotherapeutics Inc. Anti-TNF-α antibodies and their uses
CN101875694B (zh) * 2009-04-28 2014-04-02 中国医学科学院基础医学研究所 TNFα的抗体及其用途
US20110082145A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
CN102167741B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
WO2011127141A1 (en) 2010-04-07 2011-10-13 Abbott Laboratories TNF-α BINDING PROTEINS
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
WO2013063114A1 (en) * 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
AU2012328917B2 (en) 2011-10-24 2017-05-25 Abbvie Inc. Bispecific immunobinders directed against TNF and IL-17
JP2014533659A (ja) 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
MX373485B (es) * 2014-03-26 2020-04-27 Cell Medica Switzerland Ag Miembros de unión al factor de necrosis tumoral (tnf) alfa.
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
WO2018227604A1 (en) * 2017-06-16 2018-12-20 Huawei Technologies Co., Ltd. Methods and apparatus for polar encoding
CA3093422A1 (en) 2018-03-19 2019-09-26 Bioventures, Llc Periostin antibodies and methods of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2078518T3 (es) * 1990-04-05 1995-12-16 Roberto Crea Mutagenesis por desplazamiento completo.
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
EP1495142B1 (en) * 2002-04-17 2007-09-26 Bioren, Inc. "doping" in walk-through mutagenesis
AU2004254352A1 (en) * 2003-06-27 2005-01-13 Roberto Crea Look-through mutagenesis

Also Published As

Publication number Publication date
CA2573259A1 (en) 2006-02-09
US20060024308A1 (en) 2006-02-02
MX2007000104A (es) 2007-07-18
EP1769003A1 (en) 2007-04-04
WO2006014477A9 (en) 2006-03-16
WO2006014477A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
BRPI0511448A (pt) anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências
DK1139101T3 (da) Immunobestemmelse for C-reaktivt protein
MX2020000435A (es) Anticuerpos anti-cd166 y usos de estos.
ATE480562T1 (de) Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
SE0401601D0 (sv) Protofibril specific antibodies and uses thereof
NZ701444A (en) Antibodies to matrix metalloproteinase 9
NZ607711A (en) Antibodies directed to her-3 and uses thereof
NZ585622A (en) Hepatitis c virus antibodies
DK1819830T3 (da) Fremgangsmåder til antistofgenerering
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
EP0728215A4 (en) METHOD FOR BINDING MATERIAL TO THE -g (b) AMYLOID PEPTIDE
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
NZ599683A (en) Anti-ilt7 antibody
DK2067788T3 (da) Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
ATE479710T1 (de) Bispezifische antikörper
CY1111966T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων
EP3202786A3 (en) Sequence based engineering and optimization of single chain antibodies
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
HRP20161398T1 (hr) Anti-idiotip-protutijelo protiv protutijela koje je protiv amiloid-beta-peptida
NZ594682A (en) Fully human antibodies specific to cadm1
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.